Gender, Cardiovascular Disease, and the Sexism of Obesity∗  by Bairey Merz, C. Noel et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 6 6 , N O . 1 8 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 8 . 8 6 0EDITORIAL COMMENTGender, Cardiovascular Disease, and the
Sexism of Obesity*
C. Noel Bairey Merz, MD,y Holly S. Andersen, MD,z Chrisandra L. Shufelt, MD, MSySEE PAGE 1949C ardiovascular disease (CVD) continues to killmore women than men annually in theUnited States (1), and although CVD death
rates have declined in older women concomitant
with the declines in older and young men, rates
have actually increased in younger women (2). The
WISE (Women’s Ischemic Syndrome Evaluation) (3)
and VIRGO (Variation in Recovery: Role of Gender
on Outcomes of Young Acute Myocardial Infarction
Patients) (4) studies were appropriately funded by
the National Heart, Lung, and Blood Institute to
investigate this important issue. WISE, designed to
improve diagnosis and prognosis of ischemic heart
disease in women, has made numerous contributions,
including the description of “female-pattern” coro-
nary microvascular dysfunction, which is relatively
prevalent in younger women (5) and contributes to
the underdiagnosis and misdiagnosis of CVD and
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to the contents of this paper to disclose.to investigate the adverse mortality in younger
women with acute myocardial infarction (AMI), eval-
uated young (<55 years) women and men with AMI
deﬁned as symptoms and a positive biomarker and
has prospectively conﬁrmed the relatively adverse
outcomes in the young women compared with the
young men (4), as previously described in multiple
prior studies.In this issue of the Journal, in the study by
Leifheit-Limson et al. (7) a new VIRGO analysis
demonstrates that despite having a similar or greater
risk factor burden, women are 11% less likely to have
been told they are at risk and are counseled re-
garding risk modiﬁcation 16% less often than men.
Accordingly, these new results suggest that the ris-
ing epidemic of CVD in younger women may be
attributable in part to a lack of risk assessment and
preventive therapy. These results are concordant
with an extensive body of literature that documents
that women are less likely to receive all effective
guideline-indicated cardiovascular therapy (8). Clos-
ing this guideline gap could potentially eliminate the
adverse CVD mortality persistently experienced by
women.
Why do these gaps exist, despite 20 years of
awareness and guideline campaigns? We and others
have described important biological gender differ-
ences that contribute to health disparities for women.
Speciﬁcally, the female pattern of CVD, mechanisti-
cally driven by biological gender differences in
metabolism, hormones, and the autonomic nervous
system, is not detected by male-pattern diagnostics,
and no major trials have addressed treatment strate-
gies (6), which contributes to treatment and outcome
disparities. The current VIRGO results, however,
elaborate on an additional contributor: cultural
gender differences, deﬁned as the sociocultural
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1959attributes of women and men (both patients and
providers) that appear to be contributing to adverse
CVD outcome disparities in women.
Similar to prior studies, the VIRGO women were
more likely to be diabetic than VIRGO men. Indeed,
diabetes is a relatively more potent risk factor for
women, with a hazard ratio double that of men (9).
Thus, it makes sense that the VIRGO women were
more often diabetic; diabetes is a risk factor with an
evidenced-based biological gender difference of rele-
vance to the condition (AMI) of interest. Conversely,
men were more likely to have dyslipidemia, despite an
absence of evidence-based sex differences in risk or
treatment of this risk factor (10). Because dyslipide-
mia was deﬁned in large part by prior treatment, this
likely reﬂects a cultural gender bias whereby men are
more often prescribed guideline-indicated lipid-
lowering therapy than risk-matched women (11).
Paradoxically, the higher frequency of diabetes
among the women should have dictated a relatively
higher statin use than seen among men, because
guidelines have indicated this group as a CVD equiv-
alent for >20 years (12), which is sad evidence of an
important gender bias–guideline gap that adversely
impacts women.
Notably, VIRGO women were more often obese
than the men. Gender differences in obesity again
paradoxically demonstrate that male-pattern visceral
obesity is a risk factor (13), whereas general female-
pattern obesity is not. Indeed, body weight is not
included in any CVD risk prediction score (14).
General obesity is not an independent risk factor
and does not improve CVD risk prediction in women
or men. To evidence this sometimes surprising
point, CVD mortality has continued to fall despite
a robust obesity epidemic in which 74% of men
and 64% of women are now overweight/obese (15),
and obesity reduction trials have failed to reduce
CVD (16).
So if obesity is not a risk factor or treatment target
for CVD, why were the women in VIRGO more obese
than the men? A cultural gender bias is again likely.
Sexism is deﬁned as attitudes or behavior based
on traditional stereotypes of gender roles, including
the sexual objectiﬁcation of women (17). Prior
study demonstrates that women are relatively more
“objectiﬁed” in society, that is, judged by their
appearance and physical attributes, than men, and
indeed, women themselves reﬂect this gendered
societal stance by expressing more concern about
their bodyweight than men (18). Prior work con-
ﬁrms that women’s CVD risk is underestimated byhealth care providers (19). This suggests that health-
care providers are assessing CVD risk in women ac-
cording to objectiﬁed appearance/body weight rather
than validated risk factors. The VIRGO data extend
this literature to support the concept of a sexism/
objectiﬁcation cultural gender bias whereby obese
young women are more likely evaluated and there-
fore diagnosed with AMI.
New national survey data from the Women’s Heart
Alliance support the concept that this misogyny
impacts preventive heart care. Our nationally repre-
sentative survey demonstrates that women report
they are most often advised by health care providers
that they are overweight/obese rather than assessed
for validated risk factors when discussing heart dis-
ease risk (20). Further survey results indicate that
women absorb this misogynistic messaging and
report deferring visits to health care providers “until
they have lost some weight” (20). These data indicate
that heart health risk assessment and preventive
therapy are stigmatized by gendered issues of phys-
ical appearance for women.
What must be done to close gender guideline
gaps that contribute to the adverse CVD mortality in
our young women? The Women’s Heart Alliance (21)
has launched a nationwide campaign of: 1) aware-
ness to destigmatize heart disease among women
and providers (FighttheLadyKiller); 2) action to
empower women to request and providers to use
the ASCVD heart risk check (#getheartchecked); and
3) advocacy to increase heart disease research in
women (22), who now constitute the majority of
victims yet remain a minority of research subjects
(23). Providers should test themselves regarding
gender, obesity, ethnicity, and other biases using
the short and free “Implicit Bias” test (24). Prior
work demonstrates that those who ﬁrmly believe
that they are unbiased test out as the most biased
(25). The misogyny of obesity is a gendered social
stigma that contributes to women not discussing
heart health and providers failing to use evidence-
based assessment and therapy. Communication
and outreach are sorely needed to counter stereo-
types about heart disease with facts and validated
risk assessment so women and physicians can know
and practice the truth.
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